Health Affairs

Health Affairs, 27, no. 1 (2008): 33-43 doi: 10.1377/hlthaff.27.1.33 © 2008 by Project HOPE	New Online   Getting Health Reform Done   After the State of the Union   Incremental Reform   E-Health in Developing World   Most-Read Articles in 2009

This Article Figures Only Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Frank, R. G. Articles by Newhouse, J. P. Search for Related Content PubMed PubMed Citation Articles by Frank, R. G. Articles by Newhouse, J. P. Related Collections Health Reform Managed Care - Consumers Managed Care - Medicare Medicare Business Of Health Pharmaceuticals Consumer Issues Insurance Market

Medicare

Should Drug Prices Be Negotiated Under Part D Of Medicare? And If So, How?

Richard G. Frank and Joseph P. Newhouse

Medicare’s Part D prescription drug benefit has offered affordable coverage to millions of elderly Americans since its January 2006 implementation. A great deal of concern has been expressed about whether drugs are being purchased in a cost-effective manner. Many believe that the government should be negotiating prices with pharmaceutical manufacturers. We look at prescription drug pricing under Part D by examining the logic behind existing arrangements and by reviewing initial evidence on the behavior of prices. We make a modest proposal for how to improve purchasing of prescription drugs in Medicare.

                      What's this?

This article has been cited by other articles:

				K. Outterson and A. S. Kesselheim How Medicare Could Get Better Prices On Prescription Drugs Health Aff., September 1, 2009; 28(5): w832 - w841. [Abstract] [Full Text] [PDF]

				P. Neuman and J. Cubanski Medicare Part D Update -- Lessons Learned and Unfinished Business N. Engl. J. Med., July 23, 2009; 361(4): 406 - 414. [Full Text] [PDF]

				J. M. Donohue, H. A. Huskamp, and S. H. Zuvekas Dual Eligibles With Mental Disorders And Medicare Part D: How Are They Faring? Health Aff., May 1, 2009; 28(3): 746 - 759. [Abstract] [Full Text] [PDF]

				J. M. Hoffman, N. D. Shah, L. C. Vermeulen, F. Doloresco, P. K. Martin, S. Blake, L. Matusiak, R. J. Hunkler, and G. T. Schumock Projecting future drug expenditures--2009 Am. J. Health Syst. Pharm., February 1, 2009; 66(3): 237 - 257. [Abstract] [Full Text] [PDF]

				B. Siegel, H. Mead, and R. Burke Private gain and public pain: financing american health care. J. Law Med. Ethics, December 1, 2008; 36(4): 644 - 651. [PDF]

				A. B. Frakt, S. D. Pizer, and A. M. Hendricks Controlling Prescription Drug Costs: Regulation and the Role of Interest Groups in Medicare and the Veterans Health Administration Journal of Health Politics Policy and Law, December 1, 2008; 33(6): 1079 - 1106. [Abstract] [PDF]